TEXAS CENTER FOR INFECTIOUS DISEASE — History
CCN 670125 | 3-year financial timeline | COVID resilience: 66/100
🛡️ Public data only — no PHI permitted on this instance.
$14M
Latest Revenue (FY2022)
-0.1%
Revenue CAGR (3yr)
40.8%
Financial Timeline
| Metric | FY2020 | FY2021 | FY2022 | YoY (Latest) | CAGR |
|---|---|---|---|---|---|
| Net Patient Revenue | $14M | $14M | $14M | +3.3% | -0.1% |
| Operating Expenses | $13M | $13M | $8M | -33.8% | -17.9% |
| Operating Margin | 12.4% | 7.7% | 40.8% | +432.6% | +81.5% |
| Net Income | $2M | $1M | $6M | +450.1% | +81.3% |
| Licensed Beds | 50 | 50 | 50 | +0.0% | +0.0% |
| Total Patient Days | 10,282 | 9,939 | 10,267 | +3.3% | -0.1% |
| Medicare Day % | 2% | 1% | nan% | +nan% | +nan% |
| Medicaid Day % | nan% | nan% | nan% | +nan% | +nan% |
COVID Impact & Recovery
Resilience Score: 66/100 — Moderate — some COVID impact but recovering
Revenue recovery from FY2020 to FY2022: -0.1% ($14M → $14M)
FY2020 captured the initial COVID shock. Slow recovery suggests structural challenges beyond COVID.
Trend Summary
Revenue▶ Stable
Operating Margin▲ Growing
Beds▶ Stable
Medicare Mix▲ Growing
vs State Average ()
Revenue Growth
-0.1%
This Hospital
+7.6%
State Avg
Latest Margin
40.8%
This Hospital
-4.6%
State Avg
Projections (FY2023-2025)
Extrapolated from 3-year trend using linear projection. Does not account for regulatory or market changes.
| Year | Revenue (proj) | Margin (proj) |
|---|---|---|
| FY2023 (proj) | $14M | 55.0% |
| FY2024 (proj) | $14M | 69.2% |
| FY2025 (proj) | $14M | 83.5% |